Clinical trials: Total Hip Replacement Surgery
Arthroplasty, Replacement, Hip, Blood Transfusion
Comparison in Need for Bank Blood Between Patients Undergoing Total Hip Surgery That Either Receive Their Own Blood Back or Not
The study is a prospective, controlled, randomised and assessor blind study that investigate if the need for bank blood transfusion could be reduced in patients, undergoing primary or revision total hip replacement surgery, who…
- Conditions
- Arthroplasty, Replacement, Hip, Blood Transfusion, Blood Transfusion, Autologous
- Trial name
- NCT00822588
- Testing
- Sangvia® System
- Where
- 6 sites in Austria, Netherlands and 2 more
- Volunteers
- 227 people
- Sponsor
- Wellspect HealthCare
Pain, Postoperative, Analgesia
A Comparison of the Safety and Effectiveness of Two Forms of Patient-controlled Pain Medication Used After Total Hip Replacement: The E-TRANS Fentanyl Transdermal System Versus the Morphine Intravenous Pump
The purpose of this study is to compare two pain medications delivered by two different forms of patient-controlled analgesia (PCA) management systems: the Fentanyl HCl Patient-Controlled Transdermal System (E-TRANS fentanyl) and…
- Trial name
- NCT00264485
- Testing
- E-TRANS Fentanyl hydrochloride; Morphine
- Volunteers
- 799 people
- Sponsor
- Alza Corporation, DE, USA
Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE)
Deep Vein Thrombosis (DVT) Prevention in Total Hip Arthroplasty: Continuous Enhanced Circulation Therapy (CECT) Versus Low Molecular Weight Heparin (LMWH)
Evaluation of the safety and effectiveness of ActiveCare+ CECT device +/- baby dose aspirin (81 mg QD) for lowering the potential risk for bleeding and of DVT during and after THA surgery in comparison with LMWH.
- Conditions
- Deep Vein Thrombosis of Lower Limb, Pulmonary Embolism (PE), Bleeding
- Trial name
- SAFE (NCT00358735)
- Testing
- ActiveCare CECT device, Enoxaparin
- Where
- 9 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Arthroplasty, Replacement, Hip, Thrombosis
Study of the Efficacy and Safety of DU-176b in Preventing Blood Clots in Patients Undergoing Total Hip Replacement
Patients who undergo total hip replacement surgery are at greater risk of getting deep vein thrombosis (blood clots). This study evaluates the safety, tolerability and effectiveness of the study drug, DU-176b, in reducing the…
- Trial name
- NCT00107900
- Testing
- DU-176b
- Where
- United States
- Volunteers
- 606 people
- Sponsor
- Daiichi Sankyo
Hip Osteoarthritis
OXINIUM◊ DH Total Hip Arthroplasty Pivotal Study
The purpose of this study is to monitor safety of the participants implanted with the OXINIUM◊ DH Hip System up to 10-years post-implantation
- Trial name
- NCT02353377
- Testing
- OXINIUM DH Hip System, BIOLOX◊
- Volunteers
- 413 people
- Sponsor
- Smith & Nephew, Inc.
Total Hip Replacement Surgery
Pharmacokinetic Study of the Penetration of Ceftobiprole in the Bone
This study is being performed to measure the amount of the antibiotic ceftobiprole (study drug) found in the bone and blood after receiving one dose prior to your elective hip replacement surgery.
- Trial name
- NCT00771524
- Testing
- Ceftobiprole
- Volunteers
- 22 people
- Sponsor
- Basilea Pharmaceutica
Venous Thromboembolism
Xarelto Regulatory Post-Marketing Surveillance
This study is to identify the following problems and questions with respect to the safety and effectiveness of Xarelto in comparison with other pharmacologic agents in the prophylaxis of venous thromboembolism (VTE) in a large…
- Trial name
- NCT01029743
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)
- Where
- South Korea
- Volunteers
- 3,388 people
- Sponsor
- Bayer
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Primary Arthritis, Secondary Arthritis
A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery
The purpose of this study is to monitor the performance and of the Silent Hip™ in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT01383824
- Testing
- Silent™ Hip
- Where
- 9 sites in Denmark, Germany and 3 more
- Volunteers
- 89 people
- Sponsor
- DePuy International
Primary Total Hip Replacement
A DEXA Clinical Study to Evaluate the Osteointegrative Potential of Trabecular Titanium™
The purpose of this clinical trial is to evaluate the osteointegrative potential of the Trabecular TitaniumTM and to measure the pattern of changing in bone mineral density (BMD) around an uncemented acetabular cup, manufactured…
- Trial name
- NCT02635581
- Testing
- Delta TT acetabular cup
- Where
- 4 sites in Italy
- Volunteers
- 84 people
- Sponsor
- Limacorporate S.p.a
Osteoarthritis, Rheumatoid Arthritis
A Randomised Trial Comparing Anterior Versus Posterior Approach in Total Hip Replacement
This is a single-centre, randomised, prospective clinical follow-up study to evaluate clinical outcome and gait analysis after total hip arthroplasty using the standard postero-lateral approach or the minimally invasive anterior…
- Trial name
- NCT01106560
- Testing
- Minimally Invasive Anterior Approach, Standard postero-lateral approach
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- Medacta International SA
Osteoarthritis, Hip, Traumatic Arthritis of Hip
Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement
The purpose of this study is to document the clinical outcomes of several devices used in total hip replacement, including the Answer® hip stem, the Ranawat/Burnstein® acetabular shell, and Simplex® or Palacos® bone cement.
- Trial name
- NCT00588861
- Testing
- Answer® hip stem
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Biomet Orthopedics, LLC
Venous Thromboembolism
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
- Trial name
- NCT00329628
- Testing
- Rivaroxaban (BAY59-7939), Enoxaparin
- Where
- 215 sites in United States, Argentina and 26 more
- Volunteers
- 4,541 people
- Sponsor
- Bayer
Total Knee Replacement, Total Hip Replacement
New Oral Anticoagulant Therapy for the Prevention of Blood Clots Following Hip or Knee Replacement Surgery
LY517717 (a capsule given by mouth) is a blood thinner that may prevent blood clots from forming in the legs and may prevent those blood clots from traveling to the lungs.
- Trial name
- NCT00074828
- Testing
- LY517717, enoxaparin
- Where
- 8 sites in Australia, Austria and 6 more
- Volunteers
- 511 people
- Sponsor
- Eli Lilly and Company
Osteoarthritis(Primary)
A Randomised Multi-centre Study to Compare the Short-term Outcomes of Minimally Invasive and Conventional Surgery in Primary Total Hip Replacement
The purpose of this study is to compare the short-term outcomes of two surgical techniques, minimally invasive and conventional, when used in the treatment of patients with hip joint disease requiring a total hip replacement.
- Trial name
- NCT00208416
- Testing
- DePuy MI System, Conventional surgical technique
- Where
- 2 sites in United Kingdom
- Volunteers
- 58 people
- Sponsor
- DePuy International
Osteoarthritis, Post-traumatic Arthritis
A Randomised Single Centre Study to Compare the Long-term Wear Characteristics of Marathon™ and Enduron™ Polyethylene Cup Liners in Primary Total Hip Replacement
The purpose of this study is to compare the performance and compare the wear characteristics of two polyethylene cup liners, Marathon™ and Enduron™, in the treatment of patients with hip joint disease requiring a total hip…
- Conditions
- Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders, Avascular Necrosis
- Trial name
- NCT00208442
- Testing
- Marathon™, Enduron
- Where
- New Zealand
- Volunteers
- 122 people
- Sponsor
- DePuy International
Primary Osteoarthritis, Secondary Osteoarthritis
Anthology Hip Replacement System - Orthopaedic Data Evolution Panel (ODEP) Surveillance Study
This clinical study will verify the clinical and radiographic performance of the prosthesis when used in human subjects over a period of 10 years. All complications will be documented.
- Conditions
- Primary Osteoarthritis, Secondary Osteoarthritis, Avascular Necrosis, Primary Total Hip Replacement (THR)
- Trial name
- NCT04425603
- Testing
- Anthology Hip Replacement System
- Where
- 4 sites in United Kingdom
- Volunteers
- 270 people
- Sponsor
- Smith & Nephew Orthopaedics AG
Arthritis, Degenerative
Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System
The purpose of this study is to assess the early and long term safety and efficacy of the hard-on-hard total hip replacement system (R3 ODH-ODH utilization) in patients with non-inflammatory arthritis.
- Trial name
- NCT02154516
- Testing
- ODH Hip System
- Where
- 2 sites in South Africa
- Volunteers
- 26 people
- Sponsor
- Smith & Nephew, Inc.
Thromboembolism
Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)
The purpose of this study is to find the best possible (optimal) dose (effect versus adverse events) of YM150 to prevent the risk of blood clot formation after scheduled hip replacement surgery.
- Trial name
- NCT00353678
- Testing
- YM150
- Where
- 79 sites in Austria, Bosnia and Herzegovina and 15 more
- Volunteers
- 1,141 people
- Sponsor
- Astellas Pharma Inc
Venous Thromboembolism
Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty
The primary objective of the trial is to demonstrate non-inferiority of 220 mg oral dabigatran etexilate compared to 40 mg subcutaneous enoxaparin administered once daily.
- Trial name
- NCT00657150
- Testing
- Enoxaparin, Dabigatran etexilate
- Where
- 108 sites in United States, Australia and 17 more
- Volunteers
- 2,055 people
- Sponsor
- Boehringer Ingelheim